Literature DB >> 12381042

Acoustic variations in reading produced by speakers with spasmodic dysphonia pre-botox injection and within early stages of post-botox injection.

Christine M Sapienza1, Michael P Cannito, Thomas Murry, Ryan Branski, Gayle Woodson.   

Abstract

Acoustic analysis of a reading passage was used to identify the abnormal phonatory events associated with adductor spasmodic dysphonia (ADSD) pre- and postinjection of Botulinum Toxin A (Botox). Thirty-one patients (age 22 to 74 years) diagnosed with ADSD were included for study. All patients were new recipients of Botox, and the examination of their voice occurred before and after their initial injection of Botox. Acoustic events were identified from reading samples of the Rainbow Passage produced by each of the patients. These events were examined from sentences containing primarily voiced sound segments. Dependent variables included the number of phonatory breaks, frequency shifts, and aperiodic segments--all variables previously defined by the investigators. Additionally, calculated variables were made of the percentage of time these events occurred relative to the duration of the cumulative voiced segments. A sex- and age-matched control group (+/-2 years) was included for statistical comparison. Results indicated that those with ADSD produced more aberrant acoustic events than the controls. Aperiodicity was the predominant acoustic event produced during the reading, followed by frequency shifts and phonatory breaks. Within the ADSD group, the number of atypical acoustic events decreased following Botox injection. It is important that the occurrence of specific abnormal acoustic events was sufficient to differentiate the disordered speakers from the controls following as well as preceding initial Botox injection, as indicated by discriminant function analysis. This paper complements our previous work using this acoustic analysis method for defining the abnormal events present in the voice of those with ADSD and further suggests that these measures can be used in conjunction with perceptual impressions to differentiate speakers on the basis of initial severity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12381042     DOI: 10.1044/1092-4388(2002/067)

Source DB:  PubMed          Journal:  J Speech Lang Hear Res        ISSN: 1092-4388            Impact factor:   2.297


  7 in total

1.  Vocal exercise versus voice rest following botulinum toxin injections: a randomized crossover trial.

Authors:  Randal C Paniello; Julia D Edgar; Joel S Perlmutter
Journal:  Ann Otol Rhinol Laryngol       Date:  2009-11       Impact factor: 1.547

2.  Impaired Limb Proprioception in Adults With Spasmodic Dysphonia.

Authors:  Jürgen Konczak; Joshua E Aman; Yu-Wen Chen; Kuan-yi Li; Peter J Watson
Journal:  J Voice       Date:  2015-02-27       Impact factor: 2.009

3.  A Measure of the Auditory-perceptual Quality of Strain from Electroglottographic Analysis of Continuous Dysphonic Speech: Application to Adductor Spasmodic Dysphonia.

Authors:  Keerthan Somanath; Ted Mau
Journal:  J Voice       Date:  2015-12-28       Impact factor: 2.009

Review 4.  Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high-quality research designs.

Authors:  C R Watts; D D Truong; C Nye
Journal:  J Neural Transm (Vienna)       Date:  2007-06-14       Impact factor: 3.575

5.  Adductor focal laryngeal Dystonia: correlation between clinicians' ratings and subjects' perception of Dysphonia.

Authors:  Celia Faye Stewart; Catherine F Sinclair; Irene F Kling; Beverly E Diamond; Andrew Blitzer
Journal:  J Clin Mov Disord       Date:  2017-12-13

Review 6.  Botulinum toxin injections for the treatment of spasmodic dysphonia.

Authors:  C C W Watts; R Whurr; C Nye
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 7.  Vocal aging and adductor spasmodic dysphonia: response to botulinum toxin injection.

Authors:  Michael P Cannito; Joel C Kahane; Lesya Chorna
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.